De Novo Services, LLC
Outcome
DEA issued Order to Show Cause June 6, 2024, and revoked DEA Certificate of Registration No. RD0424515 published April 23, 2025, for a decade-long pattern (2013–2023) of lacking effective diversion controls and systematic recordkeeping violations including unauthorized delivery acceptance and incomplete controlled substance invoices.
Details
De Novo Services, LLC — DEA Revocation for 10-Year Pattern of Diversion Controls and Recordkeeping Failures (2013–2025)
Outcome: DEA issued an Order to Show Cause on June 6, 2024, against De Novo Services, LLC, a substance abuse treatment provider in Salt Lake City, Utah, and revoked its DEA Certificate of Registration No. RD0424515 in a Decision and Order published April 23, 2025, based on a decade-long pattern (2013–2023) of lacking effective controls against controlled substance diversion and numerous recordkeeping violations.
De Novo Services, LLC is a substance abuse treatment organization located in Salt Lake City, Utah, holding DEA Certificate of Registration No. RD0424515. On June 6, 2024, the DEA issued an Order to Show Cause proposing revocation of the registration, alleging that between 2013 and 2023 — a 10-year period — De Novo Services lacked effective controls and procedures to guard against the diversion of controlled substances and committed numerous recordkeeping violations in violation of the CSA's implementing regulations and Utah state law.
The specific recordkeeping violations documented included: between March 2022 and June 2023, allowing two unauthorized persons to accept delivery of Schedule III controlled substances without the required written authorization documentation; on six occasions between July and November 2023, accepting delivery of Schedule III controlled substances without any signature documenting who received the delivery; between March 2022 and November 2023, having 31 incomplete Schedule III controlled substance invoices; and, due to these collective failures, being unable to produce a complete accountability audit for DEA investigators during the inspection period.
The pattern of violations spanning 2013–2023 indicated systemic rather than incidental compliance failures. The Decision and Order was published in the Federal Register on April 23, 2025.
Primary Source: De Novo Services, LLC; Decision and Order (Fed. Reg. Apr. 23, 2025)
How Crucible Prevents This
De Novo Services' decade-long recordkeeping failures — including unauthorized delivery acceptance, missing delivery signatures, and incomplete invoices — rendered controlled substance audit trails impossible for DEA investigators. Crucible's controlled substance delivery verification workflow (requiring authorized recipient signature for every scheduled drug delivery) and invoice reconciliation controls would have flagged every unauthorized acceptance as an immediate compliance failure.
Don't let this happen to your organization. See how Crucible works.
See How Crucible Works